CN1814015A - Medicine for treating hepatitis, cholecystitis and cholethiasis, and preparing method - Google Patents
Medicine for treating hepatitis, cholecystitis and cholethiasis, and preparing method Download PDFInfo
- Publication number
- CN1814015A CN1814015A CNA2005100220801A CN200510022080A CN1814015A CN 1814015 A CN1814015 A CN 1814015A CN A2005100220801 A CNA2005100220801 A CN A2005100220801A CN 200510022080 A CN200510022080 A CN 200510022080A CN 1814015 A CN1814015 A CN 1814015A
- Authority
- CN
- China
- Prior art keywords
- medicine
- cholecystitis
- cholelithiasis
- raw material
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention provides a medicine with the functions of soothing liver, regulating circulation of qi, clearing away heat, removing toxic material, relieving inflammation, stopping pain and dissolving stone for effectively curing the diseases of hepatitis, cholecystitis and cholelithiasis with obvious therapeutic effect. It is made up by using 7 Chinese medicinal materials of dida, lagotis glauca, herpetospermum pedunculosum seed, hypecoum erectum, ixeris chinensis and others through a certain preparation process.
Description
Technical field:
The present invention is relevant with medicine that is used for the treatment of hepatitis, cholecystitis, cholelithiasis and preparation method.
Background technology:
Cholecystitis, gallstone disease are the sickness rate disease with high.At present, the treatment of cholecystitis, cholelithiasis, the general state of an illness is taken antibiotic medicine and analgesic than the lighter, and this can only play mitigation.The medicine of fossilization is rare.The heavier person of the state of an illness, when having ready conditions, the treatment of can performing an operation, but surgery cost height, patient often is reluctant to accept.
Summary of the invention:
The objective of the invention is provides a kind of depressed liver-energy dispersing and QI regulating in order to overcome above deficiency, heat-clearing and toxic substances removing, anti-inflammatory analgesic, function of gallbladder promoting, lithodialysis, the medicine that is used for the treatment of hepatitis, cholecystitis, cholelithiasis that therapeutic effect is good.Another object of the present invention is for the preparation method of this medicine is provided.
The present invention treats the medicine of hepatitis, cholecystitis, cholelithiasis, is made by the raw material of following weight portion substantially:
DIDA 272～425, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 216～340, Herpetospermum caudigerum Wall. 230～330,
Radix Hypecol Erecti 115～175, bonga aconite 223～326, Herba Ixeritis chinensis 215～356,
Chrysosplenium nudicaule Bunge 215～345.
Also have 195～292 weight portion Radix Berberidis Amurensis, the Radix Aucklandiae of 208～322 weight portions, 17.5～29.5 weight portion Fel Ursi powders in the above-mentioned medicine.
Above-mentioned medicine is made by the raw material of following weight portion:
DIDA 272～425, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 216～340, Herpetospermum caudigerum Wall. 230～330,
Radix Hypecol Erecti 115～175, bonga aconite 223～326, Herba Ixeritis chinensis 215～345,
Chrysosplenium nudicaule Bunge 216～345, Radix Berberidis Amurensis 195～292, the Radix Aucklandiae 208～322,
Fel Ursi powder 17.5～29.5, starch 100～150, dextrin 20～50.
Above-mentioned medicine is made by the raw material of following weight portion:
DIDA 340, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 272, Herpetospermum caudigerum Wall. 272,
Radix Hypecol Erecti 136, bonga aconite 272, Herba Ixeritis chinensis 272,
Chrysosplenium nudicaule Bunge 272, Radix Berberidis Amurensis 238, the Radix Aucklandiae 272,
Fel Ursi powder 23, starch 120, dextrin 50.
The preparation method of medicine of the present invention is with raw material pulverizing, prepares burden in proportion, and adding at least, consumption is the water of 2 times of raw material weights, soaked at least 1 hour, and decocted secondary at least again, decoct at every turn to 30～60 minutes, filter, it is 1.0～1.4 that merging filtrate, filtrate are concentrated into 60 ℃ of following relative densities, adds ethanol and measures by volume to containing alcohol that percentage ratio is 50～75%, under 2～20 ℃ of temperature, leave standstill filtration, filtrate is concentrated, spray-dried, promptly make the extract powder medicine.
The raw material particle size of pulverizing in the above-mentioned method is less than 1.2cm, and the raw material soaking time is 1 hour, decocts 50 minutes at every turn, and containing the alcohol amount after filtrate concentrates is 60%.
In the above-mentioned method raw material decoction liquor vacuum-0.082～-adopt centrifugal decompression thin film concentration under the 0.078Mpa, 50 ℃ of conditions of vapour pressure 0.078Mpa heating-up temperature.
In the above-mentioned method alcohol deposit fluid vacuum-0.082～-adopt centrifugal decompression thin film concentration under 0.078Mpa, vapour pressure 0.04Mpa, 45 ℃ of conditions of heating-up temperature.
Add Fel Ursi powder, starch, dextrin, mixing in the above-mentioned method in the extract powder medicine again, granulate, incapsulate, promptly make the capsule formulation medicine.
In the medicine of the present invention, the DIDA bitter in the mouth, cold in nature; Function: the liver heat removing function of gallbladder promoting, jaundice eliminating cures mainly the icterohepatitis viral hepatitis; The Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) bitter in the mouth, cold in nature, function: heat-clearing and toxic substances removing, the regulating menstruation of passing through, being used for the five internal organs has heat, noxious heat in the blood system, acute, chronic hepatitis, " brilliant pearl book on Chinese herbal medicine " title " the Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) bitter in the mouth, cool in nature, can gush disease in the body, move back red Bagao heat symptom-complex, clearing away heat from blood "; The Herpetospermum caudigerum Wall. bitter in the mouth, cold in nature; Function: suppressing the hyperactive liver, eliminating pathogen in the liver, gallbladder-heat, detoxifcation is used for icterohepatitis, cholecystitis, dyspepsia, " brilliant pearl book on Chinese herbal medicine " carries, " Herpetospermum caudigerum Wall. is cool in nature, sharp, clear internal organs heat, gallbladder-heat is controlled red crust and is gone into internal organs "; The Radix Hypecol Erecti hardship, cold in nature, slightly poisonous, function: heat clearing away, detoxifcation, antiinflammatory, analgesia.Be used for conjunctival congestion, hepatitis, cholecystitis, diseases such as alimentary toxicosis; List loud, high-pitched sound bitter in the mouth, cold nature, function: clearing gallbladder heat, separate pestilent toxicity, be used for hepatitis, diseases such as cholecystitis, the Four-Volume Medical Code carries bonga aconite, and effect is to control pestilence, heat-clearing and toxic substances removing, clearing gallbladder heat; Herba Ixeritis chinensis (Herba Ixeritis Denticulatae), nature and flavor hardship, cold, clearing heat secreting bile is used for icterohepatitis, cholecystitis and disorders of meridian; Radix Aucklandiae acrid in the mouth, hardship, warm in nature; Function: heat clearing away, function of gallbladder promoting, soothing liver-QI is used for fever, headache, acute icterohepatitis that liver-gallbladder disease causes, liver cirrhosis, cholecystitis, cholelithiasis; Chrysosplenium nudicaule Bunge, cold, bitter, clearing heat secreting bile under the cathartic, are used for gallbladder-heat disease, fever, headache, cholecystitis; The Radix Berberidis Amurensis bitter in the mouth, cold in nature, function: heat clearing away, function of gallbladder promoting, control dyspepsia, diarrhoea, oculopathy etc.; The Fel Ursi heat-clearing and toxic substances removing, putrefaction-removing granulation-promoting makes eye bright, and controls cholecystitis, diseases such as jaundice, the Fel Ursi bitter cold, it is flourishing to be used for liver-heat, and card such as the swimming infantile convulsion due to the extreme heat causing wind syndrome, epilepsy clonus is used for liver-heat conjunctival congestion and swelling pain, photophobia etc.DIDA is a principal agent, and the consumption maximum cooperates Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herpetospermum caudigerum Wall., and medical materials such as Radix Hypecol Erecti have depressed liver-energy dispersing and QI regulating, heat-clearing and toxic substances removing, the effect of cholagogic and litholytic, the red crust of treatment thermal source, wet red crust of source property and hepatitis, cholecystitis, cholelithiasis effect are good.
Pharmacodynamic test of active extract shows that 1. the choleretic effect of highly significant is arranged; Test to rat oral gavage with anesthetized rat cystic duct cannula method, high, middle low dosage all can increase the choleresis of anesthetized rat by highly significant, and can significantly increase bilirubinic secretion.2. litholytic effect; External lithodialysis test and New Zealand's large ear rabbit body are implanted into the test of people's cholelithiasis, and the result shows that this product has tangible litholytic effect.3. significant antiinflammatory action is arranged; Mice ear method result of the test shows that this product can significantly alleviate the mice ear degree due to the dimethylbenzene; The rat toes swelling method result of the test that carrageenin causes shows that this product can significantly resist the rat toes swelling that carrageenin causes.Agar subcutaneous injection rat chronic granuloma result of the test shows that this product can suppress granulation hyperplasia.4. refrigeration function; Show that with exempting from foreign preteins pyrogenicity method result of the test this product can reduce by the rabbit body temperature due to the foreign preteins and raises.5. antibacterial action; The extracorporeal bacteria inhibitor test result confirms that this product is to trying 20 strain G
+G
-Bacterium has bacteriostasis, and antibacterial tests confirms that this product has obvious protective effect to the mice of golden Portugal bacterium, coli-infection in the body.6. has significant analgesic activity; Cause the mouse writhing method test through hot plate method test and acetic acid, the result shows, this product can improve the pain threshold (hot plate method) of mice, prolong time and the minimizing of turning round the body appearance and on average turn round body number of times (writhing method), 7. tangible spasmolysis is arranged: test shows that this medicine has the effect of significant loose intestinal smooth muscle.8. has immunological enhancement; The phagocytic function of mice reticuloendothelial system can be strengthened, the mice delayed hypersensitivity can be suppressed carbon granules.Experimental result shows that this product has stronger antiinflammatory, and function of gallbladder promoting, lithodialysis, antibiotic, analgesic, analgesia and enhance immunity, antianaphylactic effect are consistent with clinical effect.
Medicine of the present invention can be made into granule, tablet, electuary, capsule or other dosage form.Medicine of the present invention also can adopt conventional method to boil.
Medicine of the present invention has carried out toxicologic study and clinical research:
Toxicologic study
(1) acute toxicity test: give mouse stomach this product, twice result of the test calculated with the Bliss method, records the LD of this product respectively
50=295742 ± 2.5054g/kg and 26.5g ± 2.3979g/kg, average LD
50Be 28.0375g/kg.Prompting, though this medicine has certain toxicity, toxicity is less, the employed dosage of people is safe.
(2) long term toxicity test: continuous 90 days gastric infusions of rat, routine blood test, liver, renal function detect with matched group and compare there was no significant difference, the heart, liver, spleen, lung, kidney, thymus, adrenal gland, ovary, uterus, testis, brain, stomach, duodenal histopathologic slide check no abnormality seen.Prompting, this product basic security is nontoxic, can be used for clinical.
Clinical research
Through three hospital clinical checkings, the result shows that this product can increase bile secretion, anti-inflammation, analgesic effect are arranged, acute and chronic cholecystitis is had significant curative effect, and the pain that cholecystitis and cholelithiasis are caused has tangible mitigation, and the cholesterol cholelithiasis is had the obvious treatment effect.
Liu, 58 years old, the cadre.Because of upper right abdomen pain was admitted to hospital human health screening in 3 years; Liver, spleen are little, upper right abdominal pressure pain obviously, the Mo Feishi disease positive.Abdominal B type ultrasonography sees that there is 0.2cm * 0.4cm calculus shade at the gallbladder place, diagnosis, cholelithiasis.Take medicine of the present invention after 1 week, subjective symptoms is clearly better, transference cure after January.The no abnormal discovery of having a medical check-up, B ultrasonic show that cholelithiasis discharges, and clinical cure is effective.
Patient's Drolma, women, 48 years old, cadre.Because of upper right abdomen pain 3 years repeatedly, increase the weight of to be admitted to hospital in 2 days.Have a medical check-up: the liver spleen is little, and upper right abdominal pressure pain is obvious, the Mo Feishi disease positive.Abdominal B type ultrasonography is shown cholecystitis.Diagnosis: chronic cholecystitis.Tibetan medicine's medicine typing belongs to the wet red crust of source property, takes medicine of the present invention after 2 days, and subjective symptoms is clearly better, transference cure after 2 weeks, and the no abnormal discovery of having a medical check-up, B ultrasonic demonstration cholecystitis is cured.
Medicine depressed liver-energy dispersing and QI regulating of the present invention, heat-clearing and toxic substances removing, anti-inflammatory analgesic, function of gallbladder promoting, molten stone, treatment hepatitis, cholecystitis, cholelithiasis effect are good, safety.The preparation method of medicine of the present invention is simple.
The specific embodiment:
Embodiment 1:
The capsule medicine of the embodiment of the invention 1 treatment hepatitis, cholecystitis, cholelithiasis is made by following raw materials according:
DIDA 340g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 272g, Herpetospermum caudigerum Wall. 272g,
Radix Hypecol Erecti 136g, bonga aconite 272g, Herba Ixeritis chinensis 272g,
Chrysosplenium nudicaule Bunge 272g, Radix Berberidis Amurensis 238g, Radix Aucklandiae 272g,
Fel Ursi powder 23g, starch 120g, dextrin 50g.
The preparation method of the embodiment of the invention 1 medicine is:
1, each raw material is cleaned up; Will be except that Fel Ursi powder, starch, dextrin nine flavor raw material pulverizing such as all the other DIDA, make its particle diameter less than 1.2cm, in proportion batching;
2, except that Fel Ursi powder, supplementary product starch, dextrin, other raw material is mixed, the water logging that to add 2 times of consumptions be raw material weight was steeped 1 hour, add 8 times of water gagings again and decocted 50 minutes, leave standstill filtration, leach medicinal liquid, add 6 times of water gagings again and decocted 50 minutes, leach medicinal liquid, discard medicinal residues, merge medicinal liquid twice;
3, when medicinal liquid was 1.02 (60 ℃) through being evaporated to relative density of medicine liquid, adding concentration and be 95% ethanol, to contain the alcohol amount to the medicinal liquid be 60%, airtight below 15 ℃, placed 12 hours, and filtration discards precipitation;
4, will remove the centrifugal distilling under reduced pressure recovery ethanol of sedimentary medicinal liquid and be concentrated into relative density is between 1.16～1.22 (60 ℃), and spray-dried (inlet temperature is 130 ℃ for feed liquor speed 0.40ml/min, centrifugal rotational speed 40Hz/min) makes extract powder;
5, with wearing into superfine Fel Ursi powder and extract powder mixing, add starch and dextrin in proportion, spray an amount of 95% (volume ratio) ethanol behind the mixing to all moistenings of medicated powder, make soft material, being lower than 5.0% in drying below 50 ℃ to water content, is 0.35～0.45mm sieve series grain after the aperture, adds the magnesium stearate of particle weight 1%, mixing, after check, be filled in No. zero capsule for medicine promptly by the loading amount of 0.45g/ grain, make 1000 embodiment of the invention 1 medicines altogether.
Above-mentioned raw material decoction liquor vacuum-0.082～-adopt centrifugal decompression thin film concentration under the 0.078Mpa, 50 ℃ of conditions of vapour pressure 0.078Mpa heating-up temperature.
Above-mentioned raw material decoction liquor alcohol deposit fluid vacuum-0.082～-adopt centrifugal decompression thin film concentration under 0.078Mpa, vapour pressure 0.04Mpa, 45 ℃ of conditions of heating-up temperature.
Embodiment 2:
The capsule medicine of the embodiment of the invention 2 treatment hepatitis, cholecystitis, cholelithiasis is made by following raw materials according:
DIDA 272g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 216g, Herpetospermum caudigerum Wall. 230g,
Radix Hypecol Erecti 115g, bonga aconite 223g, Herba Ixeritis chinensis 215g,
Chrysosplenium nudicaule Bunge 216g, Radix Berberidis Amurensis 195g, Radix Aucklandiae 208g,
Fel Ursi powder 17.5g, starch 100g, dextrin 20g.
The preparation method of the embodiment of the invention 2 medicines and embodiment 1 are together.
Embodiment 3:
The embodiment of the invention 3 treatment hepatitis, cholecystitis, the capsule medicine of cholelithiasis is made by following raw materials according:
DIDA 425g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 340g, Herpetospermum caudigerum Wall. 356g,
Radix Hypecol Erecti 175g, bonga aconite 326g, Herba Ixeritis chinensis 350g,
Chrysosplenium nudicaule Bunge 345g, Radix Berberidis Amurensis 292g, Radix Aucklandiae 322g,
Fel Ursi powder 29.5g, starch 150g, dextrin 50g.
The preparation method of the embodiment of the invention 3 medicines and embodiment 1 are together.
Embodiment 4:
The embodiment of the invention 4 treatment hepatitis, cholecystitis, the medicine of cholelithiasis is made by following raw materials according:
DIDA 310g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 250g, Herpetospermum caudigerum Wall. 250g,
Radix Hypecol Erecti 125g, bonga aconite 250g, Herba Ixeritis chinensis 255g,
Chrysosplenium nudicaule Bunge 250g, Radix Berberidis Amurensis 235g, Radix Aucklandiae 240g,
Can produce tablet or pill or electuary according to a conventional method after extracting extract powder by the method among the embodiment 1 in the preparation method of the embodiment of the invention 4 medicines.
Embodiment 5:
The embodiment of the invention 5 treatment cholecystitis, the medicine of cholelithiasis is made by following raw materials according:
DIDA 310g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 310g, Herpetospermum caudigerum Wall. 300g,
Radix Hypecol Erecti 155g, bonga aconite 300g, Herba Ixeritis chinensis 315g,
Chrysosplenium nudicaule Bunge 310g, Radix Berberidis Amurensis 270g.
The preparation method of the embodiment of the invention 5 medicines boils according to a conventional method.
The various embodiments described above are that foregoing of the present invention is further described, but this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to the foregoing description.All technology that realizes based on foregoing all belong to scope of the present invention.
Claims (9)
1, the medicine of treatment hepatitis, cholecystitis, cholelithiasis, make by the raw material of following weight portion substantially:
DIDA 272～425, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 216～340, Herpetospermum caudigerum Wall. 230～330,
Radix Hypecol Erecti 115～175, bonga aconite 223～326, Herba Ixeritis chinensis 215～356,
Chrysosplenium nudicaule Bunge 215～345.
2, the medicine of treatment hepatitis as claimed in claim 1, cholecystitis, cholelithiasis is characterized in that 195～292 weight portion Radix Berberidis Amurensis in addition, the Radix Aucklandiae of 208～322 weight portions, 17.5～29.5 weight portion Fel Ursi powders.
3, the medicine of treatment hepatitis as claimed in claim 2, cholecystitis, cholelithiasis is characterized in that being made by the raw material of following weight portion:
DIDA 272～425, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 216～340, Herpetospermum caudigerum Wall. 230～330,
Radix Hypecol Erecti 115～175, bonga aconite 223～326, Herba Ixeritis chinensis 215～345,
Chrysosplenium nudicaule Bunge 216～345, Radix Berberidis Amurensis 195～292, the Radix Aucklandiae 208～322,
Fel Ursi powder 17.5～29.5, starch 100～150, dextrin 20～50.
4, the medicine of treatment hepatitis as claimed in claim 3, cholecystitis, cholelithiasis is characterized in that being made by the raw material of following weight portion:
DIDA 340, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 272, Herpetospermum caudigerum Wall. 272,
Radix Hypecol Erecti 136, bonga aconite 272, Herba Ixeritis chinensis 272,
Chrysosplenium nudicaule Bunge 272, Radix Berberidis Amurensis 238, the Radix Aucklandiae 272,
Fel Ursi powder 23, starch 120, dextrin 50.
5, the preparation method of the medicine of treatment hepatitis as claimed in claim 1 or 2, cholecystitis, cholelithiasis, it is characterized in that this method is with raw material pulverizing, prepare burden in proportion, adding at least, consumption is the water of 2 times of raw material weights, soaked at least 1 hour, decoct secondary at least again, decoct to 30～60 minutes at every turn, filter merging filtrate, it is 1.0～1.4 that filtrate is concentrated into 60 ℃ of following relative densities, add ethanol and measure by volume to containing alcohol that percentage ratio is 50～75%, under 2～20 ℃ of temperature, leave standstill filtration, filtrate is concentrated, spray-dried, promptly make the extract powder medicine.
6, the preparation method of the medicine of treatment hepatitis as claimed in claim 5, cholecystitis, cholelithiasis, the raw material particle size that it is characterized in that pulverizing are less than 1.2cm, and the raw material soaking time is 1 hour, decoct 50 minutes at every turn, and containing the alcohol amount after filtrate concentrates is 60%.
7, the preparation method of the medicine of treatment hepatitis as claimed in claim 5, cholecystitis, cholelithiasis, it is characterized in that the raw material decoction liquor vacuum-0.082～-adopt centrifugal decompression thin film concentration under the 0.078Mpa, 50 ℃ of conditions of vapour pressure 0.078Mpa heating-up temperature.
8, treatment hepatitis as claimed in claim 5, cholecystitis, the preparation method of the medicine of cholelithiasis, it is characterized in that alcohol deposit fluid vacuum-0.082～-adopt centrifugal decompression thin film concentration under 0.078Mpa, vapour pressure 0.04Mpa, 45 ℃ of conditions of heating-up temperature.
9, the preparation method of the medicine of treatment hepatitis as claimed in claim 5, cholecystitis, cholelithiasis is characterized in that adding Fel Ursi powder, starch, dextrin, mixing again in the extract powder medicine, granulate, and incapsulates, and promptly makes the capsule formulation medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100220801A CN1814015A (en) | 2005-11-18 | 2005-11-18 | Medicine for treating hepatitis, cholecystitis and cholethiasis, and preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100220801A CN1814015A (en) | 2005-11-18 | 2005-11-18 | Medicine for treating hepatitis, cholecystitis and cholethiasis, and preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1814015A true CN1814015A (en) | 2006-08-09 |
Family
ID=36906447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100220801A Pending CN1814015A (en) | 2005-11-18 | 2005-11-18 | Medicine for treating hepatitis, cholecystitis and cholethiasis, and preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1814015A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000136A (en) * | 2010-11-25 | 2011-04-06 | 西南大学 | Method for extracting components having antibacterial activity from fruit of pedunculate herpetospermum |
| CN102138525A (en) * | 2011-03-07 | 2011-08-03 | 西藏自治区高原生物研究所 | Tissue culture method of pedunculate herpetospermum fruit plant |
| CN102920860A (en) * | 2012-11-29 | 2013-02-13 | 中央民族大学 | National medicinal composition for treating liver diseases |
| CN103142937A (en) * | 2013-03-25 | 2013-06-12 | 石家庄中晶生物科技有限公司 | Medicament for treating hepatitis and preparation method thereof |
| CN103585206A (en) * | 2013-10-31 | 2014-02-19 | 济南星懿医药技术有限公司 | Preparation method of Chrysosplenium extract and its application |
-
2005
- 2005-11-18 CN CNA2005100220801A patent/CN1814015A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000136A (en) * | 2010-11-25 | 2011-04-06 | 西南大学 | Method for extracting components having antibacterial activity from fruit of pedunculate herpetospermum |
| CN102138525A (en) * | 2011-03-07 | 2011-08-03 | 西藏自治区高原生物研究所 | Tissue culture method of pedunculate herpetospermum fruit plant |
| CN102138525B (en) * | 2011-03-07 | 2012-07-18 | 西藏自治区高原生物研究所 | Tissue culture method of pedunculate herpetospermum fruit plant |
| CN102920860A (en) * | 2012-11-29 | 2013-02-13 | 中央民族大学 | National medicinal composition for treating liver diseases |
| CN102920860B (en) * | 2012-11-29 | 2015-03-18 | 中央民族大学 | National medicinal composition for treating liver diseases |
| CN103142937A (en) * | 2013-03-25 | 2013-06-12 | 石家庄中晶生物科技有限公司 | Medicament for treating hepatitis and preparation method thereof |
| CN103585206A (en) * | 2013-10-31 | 2014-02-19 | 济南星懿医药技术有限公司 | Preparation method of Chrysosplenium extract and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885856B (en) | Production method for producing medicine for treating hepatitis B by periplaneta americana extract | |
| CN1729874A (en) | Method for preparing composite powdered drink with mulberry leaf, mulberry and chrysanthemum flower | |
| CN1814015A (en) | Medicine for treating hepatitis, cholecystitis and cholethiasis, and preparing method | |
| CN1285374C (en) | Medicine for treating stomachache caused by qi and cold stagnation and technique for preparing the same | |
| CN103816417A (en) | Traditional Chinese medicine composition for treating infantile convulsion and preparation method thereof | |
| CN1903331A (en) | Traditional Chinese medicine powder for lowering hyperglycosuria and restoration | |
| CN1833658A (en) | Medicine for treatment of cardio-cerebral blood vessel diseases and diabetes, and its prepn. method | |
| CN1231239C (en) | Medicine for curing hydrocephalus, brain abscess and brain tumor and preparation process thereof | |
| CN101028488A (en) | Chinese medicine for chronic pharyngitis, esophagus inflammation and esophagus cancer | |
| CN1772257A (en) | Fatty liver treating notoginseng prepn and its prepn process | |
| CN1205993C (en) | Huaaidan pellet medicine for treating cancer and preparation method thereof | |
| CN1465387A (en) | Chinese medicine preparation for treating carcinoma of esophagus | |
| CN102805823A (en) | Traditional Chinese medicine composition for curing reflux esophagitis | |
| CN105641534A (en) | Chinese herbal medicine composition for treating sore throat and its preparation and preparation method | |
| CN1907295A (en) | Chinese medicine for treating tonsillitis and pharyngitis, and its preparation | |
| CN1931262A (en) | Common cold treating Chinese medicine prepn | |
| CN1772113A (en) | Neurosism treating Chinese medicine | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1236810C (en) | Gastritis treating Chinese medicine | |
| CN104274682A (en) | Traditional Chinese medicine composition for treating coal workers' pneumoconiosis and preparation method of traditional Chinese medicine composition | |
| CN101940722A (en) | Qibei stomach healing powder | |
| CN1579497A (en) | Traditional Chinese medicinal preparation for treating iternal-external ulcer and its preparation method | |
| CN1416879A (en) | Antilipemic Chinese medicine | |
| CN1742960A (en) | Chuanluotong Chinese medicine preparation and preparing method thereof | |
| CN1850224A (en) | Medicine for treating scald and burn and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |